Deadline Approaching: Picard Medical, Inc. (PMI) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. SmithFeb 11, 2026 1:04 PM Eastern Standard Time# Deadline Approaching: Picard Medical, Inc. (PMI) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. SmithShare-- -BENSALEM, Pa.--([BUSINESS WIRE])--Law Offices of Howard G. Smith reminds investors of the upcoming April 3, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Pi ...

Core Insights - Intuitive Surgical (ISRG) shares have decreased by 13.5% over the past three months, despite strong procedure growth and the adoption of the da Vinci 5 system in Q4 2025 [1][8] - The company's stock has underperformed compared to peers like Medtronic (MDT) and Johnson & Johnson (JNJ), which saw gains of 5.8% and 22.6% respectively [2] - The key question remains whether the fundamentals of Intuitive Surgical support a hold rating [2] Procedure Growth - Management projects a 13-15% global growth in da Vinci procedures for 2026, driven by U.S. general surgery and international market expansion [3][8] - In 2025, procedures outside the U.S. increased by 23%, making up approximately 35% of global volume, indicating improved market access and training [3] - The full commercial rollout of da Vinci 5 is expected to be a significant catalyst for growth in 2026, with utilization rates increasing [4][8] Platform Performance - The SP platform experienced an 87% growth in procedures in 2025, aided by new U.S. clearances and international uptake [5] - Ion procedures grew by 51% globally, with a focus on deeper penetration of the installed base [5] Competitive Landscape - Medtronic is investing in robotic-assisted surgery but is still early in its adoption curve compared to ISRG [11] - Johnson & Johnson is progressing towards broader robotic offerings, while Stryker has a strong position in orthopedics but is limited in soft-tissue procedures [12] Financial Outlook - Earnings estimates for Intuitive Surgical for 2026 have increased by 7% to $10.03 per share, and for 2027 by 5.6% to $11.40, indicating bullish sentiment [13] - The company anticipates gross margins of 67-68% for 2026, facing headwinds from tariffs and a higher mix of da Vinci 5 systems [14][18] Valuation - Intuitive Surgical is currently trading at a forward P/E ratio of 48.68X, which is lower than its five-year median of 71.27X but significantly higher than the industry average of 26.96X [18] Investment Recommendation - The fourth-quarter performance and 2026 outlook support a high-quality growth narrative for Intuitive Surgical, driven by procedure expansion and platform innovation [19] - Despite margin pressures, the company's scale and clinical leadership position it well for long-term value compounding [20]

We recently published 10 Stocks Delivering Massive Returns. Koninklijke Philips NV (NYSE:PHG) was one of the best performers on Tuesday. Philips soared to a new 52-week high on Tuesday, as investors cheered its strong earnings performance and upbeat business outlook over the next two years. At intra-day trading, the stock soared to its highest price of $33.44 before trimming gains to finish the session just up by 11.11 percent at $32.91 apiece. During its earnings call, Koninklijke Philips NV (NYSE:PHG ...

Core Viewpoint - Merit Medical (MMSI) shows potential for significant upside, with a mean price target of $104.27 indicating a 26.8% increase from its current price of $82.22 [1] Price Targets and Estimates - The mean estimate consists of 11 short-term price targets with a standard deviation of $9.12, suggesting variability among analysts [2] - The lowest estimate is $90.00, indicating a 9.5% increase, while the highest estimate is $122.00, suggesting a potential surge of 48.4% [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [9] Analyst Sentiment and Earnings Estimates - Analysts exhibit growing optimism about MMSI's earnings prospects, as indicated by upward revisions in EPS estimates [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.2%, with two estimates moving higher and no negative revisions [12] - MMSI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Insights - Medtronic (MDT) is expected to report quarterly earnings of $1.33 per share, a decline of 4.3% year-over-year, with revenues projected at $8.9 billion, reflecting a 7.3% increase compared to the previous year [1] Revenue Estimates - Analysts estimate 'Net Sales- World Wide Revenue- Cardiovascular' to be $3.37 billion, indicating a year-over-year increase of 10.8% [4] - 'Net Sales- World Wide Revenue- Neuroscience' is projected to reach $2.59 billion, reflecting a 5.3% increase year-over-year [4] - 'Net Sales- World Wide Revenue- Neuroscience- Cranial & Spinal Technologies' is expected to be $1.32 billion, a 6% increase from the prior year [5] - 'Net Sales- World Wide Revenue- Neuroscience- Neuromodulation' is forecasted at $505.68 million, indicating a 6.2% year-over-year change [5] U.S. Revenue Estimates - 'Net Sales- U.S. Revenue' is anticipated to be $4.53 billion, suggesting a 6.9% increase year-over-year [6] - 'Net Sales- U.S. Revenue- Neuroscience- Neuromodulation' is projected at $342.56 million, reflecting a 4.8% increase [6] International Revenue Estimates - 'Net Sales- ROW- Neuroscience- Cranial & Spinal Technologies' is expected to reach $338.62 million, indicating a 10.3% year-over-year change [6] - 'Net Sales- ROW- Neuroscience- Specialty Therapies' is projected at $335.35 million, reflecting a 7.1% increase [7] - 'Net Sales- ROW- Cardiovascular- Cardiac Rhythm & Heart Failure' is expected to be $826.64 million, indicating a 7.4% increase [8] - 'Net Sales- ROW- Diabetes' is projected at $522.47 million, reflecting a significant 14.3% increase from the previous year [8] - The consensus estimate for 'Net Sales- ROW- Cardiovascular' stands at $1.77 billion, indicating an 8.5% year-over-year change [8] Stock Performance - Medtronic shares have shown a return of +5.2% over the past month, outperforming the Zacks S&P 500 composite, which has seen a -0.3% change [9]

Core Viewpoint - CS Group has appointed Shah Teelani & Associates, a PCAOB-registered auditor based in Dubai, to consolidate all 2025 financial statements for CS Group and its subsidiaries, reflecting the company's commitment to financial governance and transparency as it expands internationally [2][3]. Group Structure and Financial Reporting - The engagement with Shah Teelani & Associates aims to align the Group's financial reporting with U.S. public company standards and integrate its international operations under a unified reporting framework [3][5]. - The consolidated audit will enhance financial clarity, streamline reporting processes, and strengthen investor confidence [3]. Strategic Focus and Growth - The 2025 consolidated financial review will include operations related to the MEDUSA hygiene and disinfectant platform and international distribution expansion [4]. - The Group is focused on expanding manufacturing partnerships, regulatory positioning, international distribution agreements, and capital markets readiness as part of its global growth strategy [5]. Company Overview - CS Diagnostics Corp. (OTCQB: CSDX) is a medical technology company with a dual-focus platform in infection control and oncology, targeting high-priority global healthcare markets [6]. - The company's portfolio includes the MEDUSA platform for disinfectant and hygiene solutions and CS Protect-Hydrogel, a tissue spacer for prostate cancer radiotherapy [7].

BURLINGTON, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2025 financial results on Wednesday, February 25, 2026, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to acces ...

Financial Calendar Update - Coloplast has updated the publication dates for its FY Financial Statements 2025/26 and the Annual General Meeting 2026, with the Financial Statements now scheduled for November 3, 2026, instead of November 5, 2026, and the Annual General Meeting moved to December 1, 2026, from December 3, 2026 [2][3] Company Background - Coloplast was founded in 1954, inspired by a nurse, Elise Sørensen, who developed the first adhesive ostomy bag to help her sister after an ostomy operation. This innovation has allowed millions to live more independent lives [5]

Company Overview - DexCom, Inc. (DXCM) is a medical device company with a market cap of $26.6 billion, specializing in continuous glucose monitoring (CGM) systems for diabetes and metabolic health management globally [1] Stock Performance - Over the past 52 weeks, DXCM shares have declined by 22.8%, underperforming the S&P 500 Index, which gained 14.4% during the same period [2] - Year-to-date, DXCM stock has risen by 2.7%, slightly outperforming the S&P 500's 1.4% gain [2] - The stock has also lagged behind the State Street Health Care Select Sector SPDR ETF (XLV), which rose by 6.2% over the past 52 weeks [3] Recent Financial Results - In Q3 2025, DexCom reported an adjusted EPS of $0.61 and revenue of $1.21 billion, both exceeding expectations [4] - Despite the strong financial results, shares fell by 14.6% the following day due to a cut in 2025 adjusted gross margin guidance from 62% to approximately 61% [4] - Management's decision not to provide 2026 guidance raised concerns about potential growth falling below market expectations and highlighted risks related to the D7 product execution [4] Analyst Expectations - For the fiscal year ending December 2025, analysts project a 26.2% year-over-year increase in adjusted EPS to $2.07 [5] - The company's earnings surprise history is mixed, with two beats and two misses in the last four quarters [5] - Among 28 analysts covering the stock, the consensus rating is a "Strong Buy," supported by 22 "Strong Buy" ratings, one "Moderate Buy," four "Holds," and one "Strong Sell" [5] Analyst Ratings - On January 20, TD Cowen analyst Josh Jennings reaffirmed a "Buy" rating on DexCom, maintaining a price target of $84 [6]

Core Insights - Edwards Lifesciences Corporation reported fourth-quarter 2025 adjusted earnings per share (EPS) of 58 cents, missing the Zacks Consensus Estimate by 5.89% and reflecting a 1.7% year-over-year decline [1] - Full-year adjusted EPS was $2.56, a 5.3% increase from 2024, but also missed the Zacks Consensus Estimate by 1.2% [2] Revenue Performance - Total sales for the fourth quarter reached $1.57 billion, marking a 13.3% year-over-year increase and surpassing the Zacks Consensus Estimate by 1.99% [3] - Full-year revenues for 2025 amounted to $6.07 billion, up 11.5% year over year, also beating the Zacks Consensus Estimate by 0.7% [3] Segment Sales Analysis - Transcatheter Aortic Valve Replacement (TAVR) sales were $1.16 billion, up 12% year over year, driven by increased focus on SAPIEN therapy [4] - Transcatheter Mitral and Tricuspid Therapies (TMTT) sales reached $155.7 million, a significant 48.3% increase from the prior year, exceeding projections [5] - Surgical Structural Heart sales totaled $253.6 million, reflecting a 3.8% year-over-year growth despite some inventory adjustments [6] Margin and Cost Analysis - Gross profit was $1.22 billion, a 12.2% increase year over year, but gross margin contracted by 77 basis points to 78.2% due to a 17.4% rise in cost of sales [7] - Selling, General and Administrative (SG&A) expenses rose 22.6% year over year to $602.9 million, while R&D expenditures decreased by 1.3% to $267.7 million [7] Future Guidance - For 2026, the company projects sales growth of 8% to 10%, with adjusted EPS expected in the range of $2.90 to $3.05 [11] - The first quarter of 2026 is projected to have total sales between $1.55 billion and $1.63 billion, with adjusted EPS in the range of 70 to 76 cents [12] Overall Performance Summary - Despite an earnings miss, Edwards Lifesciences experienced revenue growth and expressed confidence in its 2026 outlook, supported by strong quarterly performance and ongoing adoption of its therapies [13]